News & Events
Company announces trial success
31 July 2007
Phytopharm plc said it has successfully completed a Phase Ib healthy volunteer clinical study for Myogane™, a treatment for Motor Neurone Disease (MND).
Commenting on the announcement, Dr Brian Dickie, Director of Research Development, MND Association, said: “There is an urgent need for new therapeutic approaches to MND. Potential treatments such as Myogane™ that can readily access the central nervous system and induce a person’s own neurotrophic factor activity offer the potential to alter disease progression. Clinical trials in patients are now needed to validate this novel therapeutic approach.”
Myogane will now need to undergo further clinical testing in people with MND to establish its effectiveness in treating the disease. Phytopharm plc is not yet ready to commence this testing and is not currently looking for people to take part in further trials. Please check our Treatment Trials section of the website to keep up to date with future developments.
Commenting on the announcement, Dr Brian Dickie, Director of Research Development, MND Association, said: “There is an urgent need for new therapeutic approaches to MND. Potential treatments such as Myogane™ that can readily access the central nervous system and induce a person’s own neurotrophic factor activity offer the potential to alter disease progression. Clinical trials in patients are now needed to validate this novel therapeutic approach.”
Myogane will now need to undergo further clinical testing in people with MND to establish its effectiveness in treating the disease. Phytopharm plc is not yet ready to commence this testing and is not currently looking for people to take part in further trials. Please check our Treatment Trials section of the website to keep up to date with future developments.
Contact:
Notes to editors
Phytopharm is a pharmaceutical development and functional food company whose product leads are generated from medicinal plants. The company's strategy is to develop these products through ‘proof of principle’ clinical testing, and then secure partners for late stage development, sales and marketing. Laboratory, manufacturing and clinical work is outsourced to selected specialists, operating under expert in-house management. This operational structure allows access to the best external research facilities whilst maintaining low fixed overheads and a lower development cost structure.
The Motor Neurone Disease (MND) Association wants to see a world free of MND. The Association fund and promote research to help bring about an end to the disease. Until then, it does all that it can to ensure everyone with MND receives the best possible care, achieves the highest quality of life, and dies with dignity. The Association is also dedicated to supporting the families and carers of people with MND.
The MND Association’s Research Foundation is committed to raising the funds needed to support national and international research efforts to end MND. Funds raised by the Research Foundation will drive science forward, so that a cure can be found and MND will be beaten. Until that day comes, the Research Foundation is equally committed to funding research that improves the lives of people living with MND.
The Motor Neurone Disease (MND) Association wants to see a world free of MND. The Association fund and promote research to help bring about an end to the disease. Until then, it does all that it can to ensure everyone with MND receives the best possible care, achieves the highest quality of life, and dies with dignity. The Association is also dedicated to supporting the families and carers of people with MND.
The MND Association’s Research Foundation is committed to raising the funds needed to support national and international research efforts to end MND. Funds raised by the Research Foundation will drive science forward, so that a cure can be found and MND will be beaten. Until that day comes, the Research Foundation is equally committed to funding research that improves the lives of people living with MND.
